MX360889B - Forma cristalina de un compuesto usado como un antagonista del receptor mineralocorticoide y metodo de preparacion de la misma. - Google Patents
Forma cristalina de un compuesto usado como un antagonista del receptor mineralocorticoide y metodo de preparacion de la misma.Info
- Publication number
- MX360889B MX360889B MX2015008193A MX2015008193A MX360889B MX 360889 B MX360889 B MX 360889B MX 2015008193 A MX2015008193 A MX 2015008193A MX 2015008193 A MX2015008193 A MX 2015008193A MX 360889 B MX360889 B MX 360889B
- Authority
- MX
- Mexico
- Prior art keywords
- crystal form
- preparation
- receptor antagonist
- compound used
- method therefor
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229940083712 aldosterone antagonist Drugs 0.000 title abstract 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061481 Renal injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención pertenece al campo técnico de las medicinas, y se refiere a una forma cristalina de un compuesto usado como antagonista del receptor mineralocorticoide y a un método de preparación del mismo, y en particular, a un método para preparar un compuesto 2- cloro-4-{(3S,3aR)]-3-ciclopentil-7-( 4-hidroxipiperidina-1-carbonil)-3,3a,4,5-tetrahidro-2H- pirazolo[3,4-fjquinolina-2-il]benzonitrilo de la fórmula (I), una forma cristalina del mismo, un método de preparación de la forma cristalina, y el uso de la forma cristalina en la preparación de fármacos para el tratamiento y/o la prevención de una lesión renal o enfermedades cardiovasculares. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210563636 | 2012-12-22 | ||
| PCT/CN2013/090252 WO2014094664A1 (zh) | 2012-12-22 | 2013-12-23 | 作为盐皮质激素受体拮抗剂的化合物的晶型及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015008193A MX2015008193A (es) | 2016-02-05 |
| MX360889B true MX360889B (es) | 2018-11-20 |
Family
ID=50977609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008193A MX360889B (es) | 2012-12-22 | 2013-12-23 | Forma cristalina de un compuesto usado como un antagonista del receptor mineralocorticoide y metodo de preparacion de la misma. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9809589B2 (es) |
| EP (2) | EP2937348B1 (es) |
| JP (6) | JP2016503041A (es) |
| KR (1) | KR101737883B1 (es) |
| CN (1) | CN105026391B (es) |
| AU (1) | AU2013362400B2 (es) |
| BR (1) | BR112015014839B1 (es) |
| CA (1) | CA2895968C (es) |
| ES (1) | ES2897496T3 (es) |
| IL (1) | IL239581B (es) |
| MX (1) | MX360889B (es) |
| NZ (1) | NZ709361A (es) |
| RU (1) | RU2622105C2 (es) |
| SG (1) | SG11201504928XA (es) |
| WO (1) | WO2014094664A1 (es) |
| ZA (1) | ZA201504485B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ709361A (en) * | 2012-12-22 | 2016-09-30 | Kbp Biosciences Co Ltd | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor |
| WO2018054357A1 (zh) * | 2016-09-24 | 2018-03-29 | 山东亨利医药科技有限责任公司 | 含盐皮质激素受体拮抗剂的药物组合物及其用途 |
| AU2020230627B2 (en) * | 2019-03-01 | 2023-01-19 | Novo Nordisk A/S | Method for preparing tricyclic compound, and intermediate thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5245716B1 (es) * | 1970-07-10 | 1977-11-17 | ||
| CN85101404A (zh) * | 1985-05-16 | 1987-01-17 | 帝人株式会社 | 头孢菌素衍生物的生产过程 |
| JPH04235188A (ja) * | 1990-06-19 | 1992-08-24 | Takeda Chem Ind Ltd | ペネム化合物の結晶、その製造方法および抗菌剤 |
| DE4235133A1 (de) * | 1992-10-19 | 1994-04-21 | Bayer Ag | Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid |
| JP3623531B2 (ja) * | 1993-06-07 | 2005-02-23 | ビーエーエスエフ アクチェンゲゼルシャフト | 結晶質ｌ−アスコルビン酸−２−燐酸エステルマグネシウム塩の製造法 |
| EP0847647B1 (en) * | 1996-06-28 | 2003-03-12 | Koninklijke Philips Electronics N.V. | Method and arrangement for transmitting teletext pages |
| CA2263586A1 (en) | 1996-09-05 | 1998-03-12 | Eifion Phillips | Novel aryl-pyridazines |
| EP1813616B1 (en) | 2002-11-22 | 2013-03-27 | Active Biotech AB | Pyrazoloquinolines with immunomodulating activity |
| CA2596737A1 (en) * | 2005-03-21 | 2006-09-28 | Eisai R & D Management Co., Ltd. | Pyrimidine compound crystal or amorphous form and process for producing the same |
| DE102007054497B3 (de) * | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| CN102372710A (zh) * | 2010-08-18 | 2012-03-14 | 山东轩竹医药科技有限公司 | 作为盐皮质激素受体拮抗剂的并环类化合物 |
| RS54408B1 (sr) * | 2010-09-30 | 2016-04-28 | Toyama Chemical Co. Ltd. | Natrijumova so 6-fluor-3-hidroksi-2-pirazin karboksamida |
| NZ709361A (en) * | 2012-12-22 | 2016-09-30 | Kbp Biosciences Co Ltd | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor |
-
2013
- 2013-12-23 NZ NZ709361A patent/NZ709361A/en unknown
- 2013-12-23 EP EP13864994.2A patent/EP2937348B1/en active Active
- 2013-12-23 SG SG11201504928XA patent/SG11201504928XA/en unknown
- 2013-12-23 KR KR1020157019924A patent/KR101737883B1/ko not_active Expired - Fee Related
- 2013-12-23 CA CA2895968A patent/CA2895968C/en active Active
- 2013-12-23 BR BR112015014839-5A patent/BR112015014839B1/pt active IP Right Grant
- 2013-12-23 RU RU2015130222A patent/RU2622105C2/ru active
- 2013-12-23 WO PCT/CN2013/090252 patent/WO2014094664A1/zh not_active Ceased
- 2013-12-23 JP JP2015548180A patent/JP2016503041A/ja active Pending
- 2013-12-23 AU AU2013362400A patent/AU2013362400B2/en not_active Ceased
- 2013-12-23 US US14/653,933 patent/US9809589B2/en not_active Expired - Fee Related
- 2013-12-23 EP EP21194531.6A patent/EP3954688A1/en not_active Withdrawn
- 2013-12-23 CN CN201380066871.7A patent/CN105026391B/zh active Active
- 2013-12-23 MX MX2015008193A patent/MX360889B/es active IP Right Grant
- 2013-12-23 ES ES13864994T patent/ES2897496T3/es active Active
-
2015
- 2015-06-22 IL IL239581A patent/IL239581B/en active IP Right Grant
- 2015-06-22 ZA ZA2015/04485A patent/ZA201504485B/en unknown
-
2017
- 2017-07-04 JP JP2017131078A patent/JP2017165787A/ja active Pending
-
2019
- 2019-02-05 JP JP2019018876A patent/JP2019065057A/ja active Pending
-
2020
- 2020-04-16 JP JP2020073415A patent/JP6986197B6/ja not_active Expired - Fee Related
-
2021
- 2021-11-02 JP JP2021179425A patent/JP2022009922A/ja not_active Withdrawn
-
2023
- 2023-11-17 JP JP2023195879A patent/JP2024009114A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA117122C2 (uk) | Хінолонові похідні | |
| MX2013005008A (es) | Derivados de carboxamida y urea heteroaromaticos sustituidos como ligandos del receptor vanilloide. | |
| PH12014501056A1 (en) | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities | |
| MY149731A (en) | Compounds | |
| WO2012019426A8 (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
| MD4736B1 (ro) | Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia | |
| WO2011141180A8 (en) | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | |
| WO2012019430A8 (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
| MX2011011428A (es) | Derivados de acido sulfamoilbenzoico como antagonistas de trpm8. | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| PH12013500007A1 (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
| PH12015500376B1 (en) | Novel bicyclic pyridinones | |
| HK1206597A1 (en) | Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof | |
| TN2015000271A1 (en) | New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity | |
| TN2016000003A1 (en) | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | |
| MX2015000879A (es) | Proceso de sintesis de opioides mejorado. | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| MX2013006670A (es) | Derivado de 2-carboxamida-4-piperazinil-benzofurano. | |
| IL225105A (en) | Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs | |
| MX2015008193A (es) | Forma cristalina de un compuesto usado como un antagonista del receptor mineralocorticoide y metodo de preparacion de la misma. | |
| HK1201839A1 (en) | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands | |
| WO2010101538A3 (en) | New crystalline forms of tiotropium bromide | |
| TW201129363A (en) | Novel pyridine alkaloids, preparation process thereof, and the uses of the pyridine alkaloids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |